EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma

Tingting Liu, Matthew D Merguerian iD, Steven P Rowe, Christine A Pratilas iD, Allen R Chen, Brian H Ladle iD

Molecular Case Studies · 2021-08 · 7 (4) · a006064

DOI: 10.1101/mcs.a006064 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Case Studies, online erschienen am 01.07.2021. Verfasst von Tingting Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Pediatric Oncology, Baltimore, Maryland 21287, USA. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of high-risk neuroblastoma typically incorporates multiagent chemotherapy, surgery, radiation therapy, autologous stem cell transplantation, immunotherapy, and differentiation therapy. The discovery of activating mutations in ALK receptor tyrosine kinase ( ALK ) in ∼8% of neuroblastomas opens the possibility of further improving outcomes for this subset of patients with the addition of ALK inhibitors. ALK inhibitors have shown efficacy in tumors such as non-small-cell lung cancer and anaplastic large cell lymphoma in which wild-type ALK overexpression is driven by translocation events. In contrast, ALK mutations driving neuroblastomas are missense mutations in the tyrosine kinase domain yielding constitutive activation and differing sensitivity to available ALK inhibitors. We describe a case of a patient with relapsed, refractory, metastatic ALK F1174L-mutated neuroblastoma who showed no response to the first-generation ALK inhibitor crizotinib but had a subsequent complete response to the ALK/ROS1 inhibitor lorlatinib. The patient's disease relapsed after 13 mo of treatment. Sequencing of cell-free DNA at the time of relapse pointed toward a potential mechanism of acquired lorlatinib resistance: amplification of CDK4 and FGFR1 and a NRAS Q61K mutation. We review the literature regarding differing sensitivity of ALK mutations found in neuroblastoma to current FDA-approved ALK inhibitors and known pathways of acquired resistance. Our report adds to the literature of important correlations between neuroblastoma ALK mutation status and clinical responsiveness to ALK inhibitors. It also highlights the importance of understanding acquired mechanisms of resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesAnaplastic Lymphoma KinaseAntineoplastic AgentsChild, PreschoolDNA Mutational AnalysisDrug Resistance, NeoplasmFemaleHigh-Throughput Nucleotide SequencingHumansLactamsNeuroblastomaProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsPyrazolesRecurrence

Stichwörter der Autor:innen

neuroblastoma

Substanzen

AminopyridinesAntineoplastic AgentsLactamsProtein Kinase InhibitorsProto-Oncogene ProteinsPyrazolesALK protein, humanAnaplastic Lymphoma KinaseProtein-Tyrosine KinasesROS1 protein, human

Autor:innen und Institutionen

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Pediatric Oncology, Baltimore, Maryland 21287, USA.
  • Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.

ORCID-Profile: Matthew D Merguerian, Christine A Pratilas, Brian H Ladle

Zitieren

APA

Liu, T., Merguerian, M. D., Rowe, S. P., Pratilas, C. A., Chen, A. R., & Ladle, B. H. (2021). Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma. Molecular Case Studies, 7(4), a006064. https://doi.org/10.1101/mcs.a006064

Vancouver

Liu T, Merguerian MD, Rowe SP, Pratilas CA, Chen AR, Ladle BH. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma. Molecular Case Studies. 2021;7(4):a006064. doi:10.1101/mcs.a006064

BibTeX
@article{Liu2021,
  author = {Liu, Tingting and Merguerian, Matthew D and Rowe, Steven P and Pratilas, Christine A and Chen, Allen R and Ladle, Brian H},
  title = {Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma},
  journal = {Molecular Case Studies},
  year = {2021},
  volume = {7},
  number = {4},
  pages = {a006064},
  doi = {10.1101/mcs.a006064}
}
Kostenlos starten →